{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for nonoxynol root_names_name in Any Name (approximate match)
Status:
Possibly Marketed Outside US
Source:
NDA207793
(1996)
Source URL:
First approved in 1995
Source:
NDA050718
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
505G(a)(3)
(1989)
Source URL:
First approved in 1989
Source:
505G(a)(3)
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
M016
(2024)
Source URL:
First approved in 1989
Source:
ANDA072525
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
ANDA214477
(1987)
Source URL:
First approved in 1987
Source:
ANDA214477
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
21 CFR 334
(2008)
Source URL:
First approved in 1980
Source:
21 CFR 333A
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
21 CFR 333D
(2021)
Source URL:
First approved in 1968
Source:
ANDA076709
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
NCT04256824: Phase 4 Interventional Recruiting Surgical Site Infection
(2020)
Source URL:
Class:
POLYMER
Polyglactin 910, is a synthetic absorbable suture which has been synthesized by the copolymerization of a mixture of purified lactide and glycolide which are cyclic intermediates derived from lactic and glycolic acids. It is degraded by Chemical Hydrolysis, that later is absorbed and metabolized by the human body. The absorption process is followed by a mass loss and fully absorbed in 90 days. The rate of absorption of polyglactin 910 is not appreciably affected by contaminated wounds. The strength and handling polyglactin 910 are similar to those of polyglycolic acid but the knot security decreases with the coating. Polyglactin 910 causes less visible reactions in the feline linea alba than polydioxanone and surgical gut do.
Status:
Possibly Marketed Outside US
Class:
POLYMER
Status:
First approved in 2019
Class:
STRUCTURALLY DIVERSE
Status:
US Approved Rx
(1999)
Source:
BLA020744
(1999)
Source URL:
First approved in 1999
Source:
BLA020744
Source URL:
Class:
STRUCTURALLY DIVERSE
